GALDERMA
20.2.2020 09:02:05 CET | Business Wire | Press release
Galderma today announced that The New England Journal of Medicine (NEJM) has published full results from the Phase 2 study of its investigational therapy nemolizumab in adult patients suffering from moderate-to-severe prurigo nodularis (PN).
PN is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus. It frequently leads to a severe quality of life impairment. Nemolizumab is a first-in-class investigational monoclonal antibody that blocks signaling of IL-31 that play a key role in the pathogenesis of PN. Nemolizumab’s safety and efficacy have not been fully evaluated by any regulatory authority.
In this study, 70 patients with moderate to severe PN and severe pruritus were randomized to receive subcutaneous nemolizumab 0.5 mg/kg every 4 Weeks from baseline to Week 8 or matching placebo injections (at weeks 0,4 and 8). Nemolizumab met the primary endpoint of a greater improvement in Peak Pruritus Numerical rating scale (PP-NRS) from baseline to Week 4 compared to placebo. The baseline PP-NRS was 8.4 in both groups. At week 4, in nemolizumab arm PP-NRS was reduced from baseline by 4.5 (53.0%) compared to 1.7 (20.2%) in placebo; P<0.001. All the other measures showed a significant difference in patients taking nemolizumab. At week 18 (10 weeks after the last dose), 38 percent of the patients who received nemolizumab were clear or almost clear of PN compared to 6 percent of the patients who received placebo; P=0.001. Nemolizumab was well tolerated and no imbalance in adverse events was observed between the two groups. The full publication is available at https://www.nejm.org/doi/full/10.1056/NEJMoa1908316
“Prurigo nodularis is known to have a profoundly negative impact on quality of life of patients, and despite significant unmet needs, there are currently no registered therapeutic options” said Dr Thibaud Portal, Global Head of Prescription medicines at Galderma. “The Phase 2 study results indicate that nemolizumab may have a key role to play for patients with moderate to severe prurigo nodularis. We are fully committed to test this drug further in Phase 3 studies and determined to bring solutions for patients suffering from prurigo nodularis.”
“The New England Journal of Medicine publication brings important attention to prurigo nodularis, where it has been very challenging for clinicians to take care of their patients in the absence of any registered therapy targeting prurigo nodularis” said Sonja Ständer, M.D., Center for Chronic Pruritus, Department of Dermatology, University of Münster, Germany and lead author of the NEJM paper. “We are encouraged by the consistent findings across this study and look forward to further clinical investigation with nemolizumab.”
In November 2019, the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associated with PN. Galderma is actively preparing for the initiation of a Phase 3 pivotal program with nemolizumab in adult patients with PN in 2020.
About Nemolizumab
Nemolizumab, a first-in-class humanized monoclonal antibody, is directed against the IL-31 receptor alpha, which blocks signaling from IL-31. Nemolizumab, initially developed by Chugai Pharmaceutical Co., Ltd., was subsequently licensed to Galderma in 2016 – worldwide except Japan and Taiwan. Nemolizumab is an investigational agent under clinical development and its safety and efficacy have not been fully evaluated by any regulatory authority.
About Galderma
Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio of prescription medicines, aesthetics solutions and consumer care products. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200220005309/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approval Granted for Commercial Manufacturing at Rezon Bio's Warsaw-Duchnice Facility18.2.2026 14:01:00 CET | Press release
Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar. This milestone represents an important step in the continued development of Rezon Bio’s global manufacturing network and reflects the company’s focus on building robust, compliant, and reliable capabilities to support biologic therapies for patients worldwide. The FDA approval of the Warsaw-Duchnice facility follows a comprehensive review process and reflects the maturity of the site’s quality systems, technical capabilities, and operational readiness for commercial supply to the US market. This approval is coming subsequent to previous EMA GMP certification and approval for commercial supply to European markets. Such approval further strengthens Rezon Bio’s ability to support clients in needs to supply EU and US territories and enhances its position as a reliable partner within the Contract Development and Manufa
Vasion® Achieves FedRAMP® High Authorization, Meeting Federal Cloud Security Gold Standard18.2.2026 14:00:00 CET | Press release
FedRAMP Authorization validates Vasion’s secure, cloud-native, intelligent physical and digital print automation platform as trusted to modernize federal agency operations. Vasion, a leader in serverless printing and Intelligent Print Automation, today announced it has achieved FedRAMP® High Authorization to Operate (ATO) through the Federal Risk and Authorization Management Program. This authorization represents the most rigorous security compliance standard for the government sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218295773/en/ At V3, Vasion Co-Founder and CEO Ryan Wedig unveiled the Intelligent Print Automation platform and challenged every Vasioneer to embrace a Mission of Aspirational Performance that demands collaboration, creativity, and courage. With Vasion's recent FedRAMP High Authorization, the company is making digital transformation attainable for everyone, including federal agencies with the
TreviPay Announces AI-Powered Growth Center to Help Enterprises Predict Buyer Behavior and Drive B2B Sales18.2.2026 14:00:00 CET | Press release
The new product offering uses machine learning to support targeted buyer engagement and rebate incentives TreviPay, a fully managed B2B payments platform, today announced the availability of the Growth Center, a set of capabilities within the TreviPay Client Portal to help identify buyer growth opportunities more strategically and build stronger, longer-lasting supplier relationships. With its advanced features, the new Growth Center enables businesses to explore buyer needs, spot trends and optimize key steps in the order-to-cash (O2C) process. Integrated into TreviPay’s global payments network, the customizable add-ons will help businesses use their O2C programs to deepen buyer relationships and drive lasting engagement. For many suppliers, growth is not only about bringing in new buyers. It also means keeping existing buyers engaged, spotting early signs of dormancy and giving sales, operations and finance teams a practical way to act without adding friction. By combining transactio
ICR Appoints Sukanti Ghosh as Partner, International Strategy & Markets18.2.2026 13:00:00 CET | Press release
Global Strategic Communications leader to drive ICR's expansion across Europe, Middle East, South Asia, and Africa ICR, a leading strategic communications and advisory firm, today announced the appointment of Sukanti Ghosh as Partner, International Strategy & Markets, effective February 2, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218511412/en/ Sukanti Ghosh headshot Based in London, Mr. Ghosh brings more than three decades of experience in global corporate affairs, financial communications, strategy, and issues management to ICR as the firm continues to grow its international footprint in Europe and across the Middle East, South Asia, and Africa. Mr. Ghosh joins ICR from the Vedanta Group, a $20bn diversified mining, energy and technology conglomerates, where he served as President of Global Policy & Communications and led financial communications for the group, globally. During his tenure, he also played a ce
Macrobond Recognized in G2’s 2026 Best Software Awards for Financial Services and New Software18.2.2026 13:00:00 CET | Press release
Macrobond, the global platform for macroeconomic and financial data, today announced it has been named to G2’s 2026 Best Software Awards, earning recognition in the Best Financial Services Software Products and Best New Software Products categories. As the world’s largest and most trusted software marketplace, G2 reaches more than 100 million buyers annually. Its annual Best Software Awards rank the world’s leading software companies and products based on authentic, timely reviews from real users. “As buyers increasingly shift to AI driven research to discover software solutions, being recommended in the answer moment must be earned with credible proof,” said Godard Abel, co founder and CEO at G2. “Our Best Software Awards are grounded in trusted data from authentic customer reviews. They not only give buyers an objective, reliable guide to the products that help teams do their best work, but they are also the proof AI search platforms rely on when sourcing answers. Congratulations to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom